Results
FDA APPROVED INDICATION :
Ophthalmic Treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, Streptococcus viridans group, Acinetobacter lwoffii, Haemophilus influenzae, Haemophilus parainfluenzae, and Chlamydia trachomatis.
CONTRAINDICATION/PRECAUTION
- Hypersensitivity reaction may occur. Discontinue at first sign.
- Prolonged use may result in overgrowth of nonsusceptible organisms.
ADVERSE EFFECTS
Ophthalmic: The most frequently reported adverse events were conjunctivitis, decreased visual acuity, keratitis, dry eye, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. Nonocular-related adverse events included fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.
ADMINISTRATION
Ophthalmic For topical ophthalmic use only. Do not inject subconjunctivally or introduce directly into the anterior chamber of the eye